Avalyn Pharma Inc(AVLN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 22 at 4:00 PM ET (Korea 10/23 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 39.92% | Shs Outstand | 44.3M | Perf Week | 10.59% |
| Market Cap | 1.21B | Forward P/E | - | EPS next Y | 9.65% | Insider Trans | 8.52% | Shs Float | 26.6M | Perf Month | -8.16% |
| Enterprise Value | 0.87B | PEG | - | EPS next Q | -0.71 | Inst Own | 66.13% | Short Float | 9.45% | Perf Quarter | -2.5% |
| Income | - | P/S | - | EPS this Y | 13.1% | Inst Trans | 170.22% | Short Ratio | 10.44 | Perf Half Y | - |
| Sales | - | P/B | 3.03 | EPS next 5Y | 7.23% | ROA | - | Short Interest | 2.52M | Perf YTD | 4.81% |
| Book/sh | 8.99 | P/C | 3.43 | EPS past 3/5Y | - | ROE | - | 52W High | -32.16% ($40.17) | Perf Year | - |
| Cash/sh | 7.95 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 22.53% ($22.24) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 7.9% 7.21% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.94 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 33.1 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 49.8 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 33.1 | Sales Q/Q | - | SMA20 | 5.24% ($25.89) | Beta | - | Target Price | $61.8 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/12 | SMA50 | -13.81% ($31.62) | Rel Volume | 1.19 | Prev Close | $25.11 |
| Employees | 50 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | -26.17% - | SMA200 | -9.74% ($30.19) | Avg Volume(3M) | 0.24M | Price | $27.25 |
| IPO | 2026/4/30 | Option/Short | Yes/Yes | Trades | 4727 | Volume | 286,750 | Change | 8.52% |
Avalyn Pharma (AVLN) is a clinical-stage biotech company developing inhaled anti-fibrotic therapies targeting rare respiratory diseases, including pulmonary fibrosis. Its strategy involves reformulating existing oral drugs into inhaled forms to deliver the medication directly to the lungs, thereby reducing side effects from systemic exposure and improving tolerability. Founded in 2011, the company is headquartered in the United States.
Over the past 1 year, roughly in the middle
32% below its 1-year high.
Traded about as much as usual. That is 119% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +13.1% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 66.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #144 of 594 in the industry
Based on market cap of $1B.
VSTM#140 Verastem Inc $1B PER - 
SLN#141 Silence Therapeutics Plc ADR $1B PER - 
OMER#142 Omeros Corp $1B PER 11.7 
SNDX#143 Syndax Pharmaceuticals Inc $1B PER - AVLN#144 Avalyn Pharma Inc $1B PER - 
FAQ
What kind of company is AVLN?
AVLN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AVLN?
The market cap of AVLN is approximately $1.2B, ranking 2,445 within its sector.
What is the 52-week high and low for AVLN?
AVLN has recorded a 52-week high of $40.17 and a low of $22.24.
